Teltow/Berlin, 13 July 2016. co.don AG, one of the leading global specialists in cell cultivation for the regenerative treatment of articular cartilage defects and spinal disc defects, has gained a new anchor investor. Bauerfeind AG, based in Zeulenroda-Triebes, holds slightly over 25 per cent of the shares in co.don AG, according to information from Bauerfeind Beteiligungsgesellschaft mbH. The former major shareholders OSEMIFARO INVESTMENTS Ltd. and TRANSNOVA INVESTMENTS Ltd. have reduced their equity interests to zero. There have been no other significant changes to the shareholder structure of co.don AG.
Dirk Hessel, CEO of co.don AG: “We are very pleased to have won Bauerfeind AG as a new entrepreneurial anchor investor with a long-term strategy. Bauerfeind AG has many years of international experience in the field of orthopaedics. There is a considerable overlap in our customer segments for innovative therapies. The synergies resulting from this strategic partnership will form a stable basis for continuing the implementation of our company’s ongoing growth strategy, both within Germany and in preparation for entering the wider EU market. We thank OSEMIFARO INVESTMENTS Ltd. and TRANSNOVA INVESTMENTS Ltd. for their support over many years.”
“Joint preservation before joint replacement is co.don’s guiding principle. For me that is more than an idea that happens to chime with the current mood. In connection with our bandages and supports I see it as a fundamental approach for a holistic therapy”, explains Prof. Hans B. Bauerfeind.
The share capital of co.don AG is EUR 16,217,344 divided into 16,217,344 shares.
Pressekontakt:
Matthias Meißner, M.A.
Corporate communications / IR / PR
+49 +49 3328 43460
Fax: +49 03328 434643
pr@codon.de
About Bauerfeind AG: Bauerfeind AG from Zeulenroda in Thuringia makes bandages, supports, medical compression tights and orthopaedic inserts. The family company was established in 1929, has international sales operations and is one of the market leaders. Bauerfeind has a total of around 2,500 employees, is based in Germany and has subsidiaries in more than 20 countries. Its premium products stand for quality “Made in Germany”.
About co.don AG: Berlin-based co.don AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage to joints following traumatic or degenerative defects. co.don condrosphere® is a cell therapy product that uses only the patient’s own cartilage cells (“autologous chondrocytes”). co.don condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. co.don condrosphere® has been used for more than 10 years in over 120 clinics to treat more than 10,000 patients. The shares in co.don AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO), Vilma Methner (COO, CSO). Further informationen can be found at www.ihre-zellzuechter.de or www.codon.de
